Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug ...

Ailux has announced a strategic collaboration with Eli Lilly and Company to accelerate the discovery and development of bispecific antibodies.

In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...

Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

Eli Lilly ( LLY +1.06%) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in Virginia. Here are two things investors should know.

Swiss pharma giant Novartis has been on a deal spree ahead of several major patent expiries. In late October it agreed a $12 ...

Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to ...

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared ...

Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...